This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

SynteractHCR Appoints Bill Pierce As Chief Information Officer And Richard Paul As Chief Medical Officer And Vice President Medical/Regulatory Affairs





SAN DIEGO, April 2, 2013 /PRNewswire/ -- SynteractHCR, a leading full-service contract research organization (CRO), has hired two new senior executives to support the company's growth on a global scale following its recent merger. SynteractHCR has appointed Bill Pierce as chief information officer and Richard Paul as chief medical officer and vice president medical/regulatory affairs. Both were chosen for their leadership experience and expertise in their respective fields; Pierce has held key leadership positions within the CRO as well as financial industries, and Paul has more than 23 years of drug development experience across several therapeutic areas.

(Logo: http://photos.prnewswire.com/prnh/20111108/MM02925LOGO)

As CIO, Pierce will be responsible for driving operational excellence, streamlining processes and delivering high returns for invested capital. He brings a strong foundation in the CRO industry and is very experienced across clinical data management platforms and technologies. He gained leadership experience across various industries, including his last position at INC Research as chief information officer. Previously he served as vice president both for Fidelity Investments and Goldman Sachs, among other leadership positions. Pierce received his degree from Boston University.

In his role as CMO, Dr. Paul will be providing global leadership and oversight for medical safety and regulatory affairs. He brings more than 23 years of clinical research, regulatory affairs, medical safety and strategic drug development experience to his new role. Prior to joining SynteractHCR, Paul held positions with QRxPharma as executive vice president of drug development where he had global responsibility for clinical research and regulatory affairs. He also served as senior vice president of global regulatory affairs at ICON Clinical Research. Paul earned his MD degree from the University of Barcelona and conducted his postgraduate medical training at Rutgers University and Harvard School of Medicine.

According to Wendel Barr, CEO of SynteractHCR, the two new hires will be instrumental in driving the company's plans for growth to meet the increasingly complex needs of its clients.

"After two decades of operations, we are known for offering our clients individualized services tailored to their specific needs. With their impressive industry experience, Bill and Richard provide additional valuable assets to our company. Leading our Information Technology group, Bill will leverage technology to drive efficiency across the projects we support and overall business productivity. Paul's expertise in medical, safety, drug development and regulatory affairs will ensure that across the continuum of our service offering, we maintain the highest quality standards with product approval the objective. I am certain that as excellent leaders, Bill and Rich will help the company grow, to further expand our offerings on a global scale." 

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs